Henry TeachingC. Heminger TeachingS.
Certain of our marketed products face, and our product candidates, if approved, are also expected to face, substantial competition, including from products marketed by large pharmaceutical corporations, which may have greater clinical, research, regulatory, manufacturing, marketing, financial and human resources than we do.
Over the next several years, many of the existing patents on our principal products will expire, and we expect to face increasing competition thereafter, including from biosimilar products. This demonstration will typically consist of comparative analytical, preclinical and clinical data from the biosimilar product to show that it has similar safety and efficacy as the reference product.
The FDA guidance documents leave room for the FDA to consider, on a case-by-case basis, the specifics of what evidence would be required for a biosimilar product to gain approval see Government Regulation.
In the European Union Table of Contents EUthere is already an established regulatory pathway for biosimilars and we are facing increasing competition from biosimilars. In the United States after patent expiration, we expect to face greater competition, including from manufacturers with biosimilar products approved in Europe that may seek to quickly obtain U.
Upon patent expiration for small molecule products, there is typically intense competition from generics manufacturers, which generally leads to significant and rapid declines in sales of the branded product.
Given that our principal products are biologics, we do not believe the impact of biosimilar competition will be as significant as with small molecule products in part because successful competitors must have a broad range of specialized skills and capabilities unique to biologics, including significant regulatory, clinical and manufacturing expertise, and since the products are similar, but not identical, the biosimilars will have to compete against a product with an established efficacy and safety record.
In some cases we may experience additional competition prior to the expiration of our patents as a result of agreements we have made in connection with the settlement of patent litigation with companies developing potentially competing products.
Further, the introduction of new products or the development of new processes or technologies by competitors or new information about existing products may result in increased competition for our marketed products, even for those protected by patents, or in a reduction of price that we receive from selling our products.
In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates.
In addition to the challenges presented by competition, our existing products and product candidates are also subject to increasing regulatory compliance requirements that could be imposed as conditions of approval or after a product has been approved.
This is increasingly true of new therapies with novel mechanisms of action. We design and implement comprehensive proactive pharmacovigilance programs for all of our products to help ensure the detection, assessment and communication of adverse effects.
When deemed necessary and appropriate, additional measures for risk communication and mitigation are designed and implemented in consultation with regulatory agencies.
As a condition of approval or due to safety concerns after a product has been approved, we may be required to perform additional clinical trials or studies, including postmarketing requirements PMRs and postmarketing commitments PMCs.
A PMR is a trial or study that a sponsor company is required by statute or regulation to conduct. A PMC is a trial or study that a sponsor company agrees to in writing, but is not required by law, to conduct.
In addition, we may be required to implement risk management plans for our products in the various regions in which they are approved. For example, in the FDA began requiring risk evaluation and mitigation strategies REMS for various approved products to ensure that the benefits of the drugs outweigh the risks.
A REMS may also be imposed as a condition of approval or after a product has been on the market. A REMS may include a medication guide or a patient package insert, a healthcare provider communication plan or elements to assure safe use that the FDA deems necessary. We currently have REMS for a number of our marketed products.
Most patients receiving our principal products for approved indications are covered by either government or private payer healthcare programs, which influence demand.
The reimbursement environment continues to evolve with greater emphasis on both cost containment and demonstration of the economic value of products. In addition, the current worldwide economic conditions have also contributed to increasing pressures on cost containment.Read chapter The Formulation of Health Policy by the Three Branches of Government: Breakthroughs in biomedicine often lead to new life-giving treatments b.
English vocabulary word lists and various games, puzzles and quizzes to help you study them. The Policy Process: Part I — Patient access to affordable health care is an ongoing issue in the United States.
The first portion of the policy process involves three different stages, the formulation stage, legislative stage, and the implementation stage. The Policy Process: Part I Susan Kunz HCS July 6, Rich Jones The Policy Process: Part I Patient access to affordable health care is an ongoing issue in the United States.
The first portion of the policy process involves three different stages, the formulation stage, legislative stage, and the implementation stage. The session of the state legislature passed the Religious Viewpoint Antidiscrimination Act, which a.
allowed outside church organizations access to school campuses. Minnesota Society of Certified Public Accountants. West 82nd Street, Ste Bloomington MN Ph: Fax: regardbouddhiste.com